Clinical Study
Urolastic—A New Bulking Agent for the Treatment of Women with Stress Urinary Incontinence: Outcome of 12 Months Follow Up
Table 1
Efficacy outcomes versus baseline (visit I) characteristics after 6 weeks (visit II), 3 months (visit III), and 12 months (visit IV).
| | Stamey grade | 1 hr pad test-weight (g) | Incontinence episodes (24 h) | I-QoL | Number of pads (72 hr) |
| Baseline () | 1.9 (0.79) | 20.2 (24.28) | 6.1 (6.70) | 50.7 (20.09) | 17.3 (14.91) | Visit II () | 0.75 (0.73)‡ | 5.5 (13.98)‡ | 2.5 (2.7)‡ | 64.0 (24.12)$ | 8.7 (8.70)‡ | Visit III () | 0.2 (0.41)‡ | 1.6 (2.80)‡ | 1.7 (1.9)‡ | 81.9 (21.30)‡ | 5.4 (7.06)‡ | Visit IV () | 0.4 (0.69)‡ | 7.8 (19.92)‡ | 1.6 (1.77)‡ | 75.5 (20.98)‡ | 5.6 (7.22)‡ |
|
|
for all visits versus baseline. for visit II versus baseline. Values presented in mean (SD).
|